Profesionales médicos

A continuación, se enumeran los ensayos clínicos actuales.

55 estudios en Digestive Diseases
(solo estudios abiertos).

Filtra esta lista de estudios por sede, estado, etc.

1. FXR Effect On Severe Alcohol-Associated Hepatitis (FRESH) Study

   Rochester, Minn.

   The purpose of this study is to assess dose-related safety, early efficacy, pharmacokinetics and pharmacodynamics of INT-787 in patients with severe alcohol-associated hepatitis (sAH).

2. Study Of Zanzalintinib In Combination With Immuno-Oncology Agents In Participants With Solid Tumors

   Jacksonville, Fla., Rochester, Minn., Scottsdale/Phoenix, Ariz.

   This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alone, and in combination with nivolumab (doublet), nivolumab + ipilimumab (triplet) and nivolumab + relatlimab (triplet) in participants with advanced solid tumors.
   
   In the Expansion Stage, the safety and efficacy of zanzalintinib as monotherapy and in combination therapy will be further evaluated in tumor-specific Expansion Cohorts.

3. A Bio-bank for Patients with Inflammatory Bowel Disease Associated Neoplasia

   Rochester, Minn.

   The purpose of this study is to collect blood and stool samples to validate and improve the performance of stool and blood DNA markers for inflammatory bowel disease and colorectal neoplasia critical to the long-term goal of improving effectiveness of neoplasia detection in patients using non-invasive biomarkers to assist colonoscopy and radiographic screening. 

4. Cohort of Patients With Fatty Liver Disease

   Jacksonville, Fla.

   The purpose of this research is to create a registry of patients having or at risk for metabolic liver disease for investigations into the molecular pathogenesis of cirrhosis, liver cancer, and end-stage liver disease.

5. Mucosal and Microbiota Changes During Acute Campylobacteriosis

   Rochester, Minn.

   Gastrointestinal (GI) infection with Campylobacter causes inflammation in the bowel and can change bacteria in the gut. Certain individuals with Campylobacter infection are also known to develop chronic bowel problems such as Irritable Bowel Syndrome (IBS). The researchers are doing this study to understand if changes in gut bacteria and gut mucosal lining during an acute infection can help identify individuals who might be at risk for developing problems in the future.